Patent SG-11201909376T-A (SG)
Title: Crystalline forms of a jak inhibitor compound
Inventor: DABROS MARTA
IPC: A61P11/00
Filed: 2018-04-30
Abstract: WO 18/ 20 4236 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT ~~ll~~~~~~~~ 011101VIIIVIIIVIII olo oi olo mom ow (10) International Publication Number WO 2018/204236 Al (51) International Patent Classification: C07D 471/04 (2006.01) A61P 11/00 (2006.01) A61K 31/4523 (2006.01) A61P 27/00 (2006.01) (21) International Application Number: PCT/US2018/030144 (22) International Filing Date: 30 April 2018 (30.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/492,571 01 May 2017 (01.05.2017) US (71) Applicant: THERAVANCE BIOPHARMA R&D IP, LLC [US/US]; 901 Gateway Boulevard, South San Fran- cisco, California 94080 (US). (72) Inventors: DABROS, Marta; 888 Foster City Boule- vard, Apt. Q2, Foster City, California 94404 (US). THAL- LADI, Venkat R.; 888 Foster City Boulevard, Apt. E3, Foster City, California 94404 (US). NZEREM, Jerry; 29 Woods Circle, South San Francisco, California 94080 (US). KLEINSCHEK, Melanie A.; 30 Elizabeth Street, San Francisco, California 94110 (US). CRATER, Glenn D.; 7108 Rippling Stone Ln, Raleigh, North Carolina 27612 (US). (74) Agent: HAGENAH, Jeffrey A. et al.; THERAVANCE BIOPHARMA US, INC., 901 Gateway Boulevard, South San Francisco, California 94080 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND (57) : The present invention provides crys- talline hydrates of the oxalate and succinate salts of 5-ethy1-2-fluoro-4-(3-(5-(1-methylpiperidin-4-y1)-4,5,6,7-tetrahy- dro-1H-imidazo[4,5-c]pyridin-2-y1)-1H-indazol-6-yl)phenol. The in- vention also provides pharmaceutical compositions comprising such crystalline hydrates, methods of using such crystalline hydrates to treat respiratory and other diseases, and processes useful for preparing such crystalline oxalate and succinate hydrates.